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Abstract
The alteration of the choline metabolite profile is a well-established characteristic of cancer cells.
In colorectal cancer (CRC), phosphatidylcholine is the most prominent phospholipid. In the
present study, we report that lysophosphatidylcholine acyltransferase 1 (LPCAT1;
NM_024830.3), the enzyme that converts lysophosphatidylcholine into phosphatidylcholine, was
highly overexpressed in colorectal adenocarcinomas when compared to normal mucosas. Our
microarray transcription profiling study showed a significant (p<10−8) transcript overexpression in
168 colorectal adenocarcinomas when compared to ten normal mucosas. Immunohistochemical
analysis of colon tumors with a polyclonal antibody to LPCAT1 confirmed the upregulation of the
LPCAT1 protein. Overexpression of LPCAT1 in COS7 cells localized the protein to the
endoplasmic reticulum and the mitochondria and increased LPCAT1 specific activity 38-fold. In
cultured cells, overexpressed LPCAT1 enhanced the incorporation of [14C]palmitate into
phosphatidylcholine. COS7 cells transfected with LPCAT1 showed no growth rate alteration, in
contrast to the colon cancer cell line SW480, which significantly (p<10−5) increased its growth
rate by 17%. We conclude that LPCAT1 may contribute to total choline metabolite accumulation
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via phosphatidylcholine remodeling, thereby altering the CRC lipid profile, a characteristic of
malignancy.
Keywords
Colorectal cancer; Lysophosphatidic acyltransferase; Microarrays; Lipid metabolism;
Phosphatidylcholine
Introduction
Colorectal cancer (CRC) is the third most common cancer worldwide and caused almost
500,000 deaths in 2003 according to the World Cancer Report [1]. In a previous publication
that analyzed pooled samples, it was discovered that an expressed sequence tag representing
FLJ12443 (now known as AYTL2) was upregulated in CRC tissues [2]. We have now
confirmed and expanded the previous observation in this new study that examined 168
colorectal adenocarcinomas and ten normal mucosa samples. We report that the AYTL2
transcript was highly upregulated (2.5-log2-fold change) in CRC when compared to normal
mucosa (p<10−8). The encoded protein from mouse, rat, and humans for AYTL2,
lysophosphatidylcholine acyltransferase 1 (LPCAT1; NM_024830.3), was recently
characterized [3–5]. In mice and rats, LPCAT1 is predominantly expressed in lung,
particularly in alveolar type II cells, where it is hypothesized to play a fundamental role in
the biosynthesis of surfactant dipalmitoyl phosphatidylcholine (PtdCho). In addition,
LPCAT1 shows lysophosphatidylcholine acyltransferase activity when overexpressed in
COS7 or HK293 cells and has a preference for palmitate incorporation. Surprisingly,
however, the human LPCAT1 was reported to be an acylglycerol-3-phosphate
acyltransferase isoform (called AGPAT9), which lacked LPCAT activity when
overexpressed in hamster CHO cells [5].
In higher eukaryotes, PtdCho is synthesized via two pathways, the triple methylation of
phosphatidylethanol-amine (PtdEtn) and the CDP-choline pathway [6]. Remodeling allows
PtdCho to exchange acyl chains by consecutive deacylation and reacylation reactions to
achieve a steady-state composition of PtdCho species (Fig. 1). In the specific environment of
type II pneumocytes, LPCAT1 is likely to be critical for the synthesis of
dipalmitoylphosphatidylcholine by enzymatically transferring palmitoyl-CoA to the sn-2
position of sn-1 palmitoyl-lysophosphatidylcholine [4].
PtdCho is the most abundant phospholipid in both normal and malignant tissues [7,8]. In
colon cancer tissues, the amount of phospholipid is highly increased [8], and increased
synthesis of membrane phospholipids is required for rapid growth during tumor
development [8]. In addition, changes in superficial membrane potential and phospholipid
composition are associated with malignancy [9], and alterations of membrane lipid levels
can also influence cell proliferation and viability [10].
In the present study, LPCAT1 was upregulated at both the transcript and protein levels in
human colorectal adenocarcinomas when compared to normal mucosa. In COS7 cells,
transiently overexpressed hLPCAT1 co-localized both to the endoplasmic reticulum (ER)
and the mitochondria. Overexpression of LPCAT1 in COS7 cells showed no growth rate
alteration, in contrast to the colon cancer cell line SW480, which showed a significant
(p<10−5) increase in growth rate. When overexpressed, hLPCAT1 catalyzed the reacylation
of LysoPtdCho and had a preference for palmitoyl-CoA as its substrate. Our results suggest
that, in CRC, upregulation of hLPCAT1 may contribute to increased recycling of PtdCho via
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We analyzed 168 colorectal tissue samples from patients in Denmark (n=108), The
Netherlands (n=56) and Finland (n=14), comprising 122 colon and 46 rectum cancers from
Dukes stages A (1), B (149), C (13), and D (5), as described in Table 1. Ten normal mucosa
biopsies from the resection edge were collected from Danish patients. Informed consent was
obtained from patients, and the local scientific ethical committees approved the study.
Tissue handling, nucleic acid isolation, microsatellite analysis, gene expression analysis, and
real time RT-PCR
The specimens were obtained fresh from surgery, immediately snap frozen and processed as
previously described [11]. The microsatellite status of the tumors was analyzed as
previously described [11]. Tumors with low-frequency MSI have similar clinical features as
MSS tumors and were considered as such in this study. The readings from the quantitative
scanning were analyzed by the Affymetrix Software MAS5.0. The resulting cell files for all
samples were imported into ArrayAssist version 3.3 (Stratagene), and data were normalized
using GC Robust Multi-array Average as implemented in ArrayAssist. P values in all
experiments were calculated using a two-sided double t test with unequal variances.
Labeling of RNA, hybridization, and scanning was performed as described [11].
Semi-quantitative real-time RT-PCR was performed on 20 samples, five microsatellite
unstable (MSI) and five microsatellite stable (MSS), and their corresponding matching
normal mucosa. Complementary DNA (cDNA) was synthesized as described [11]. RT-PCR
analysis was performed in triplicates using TaqMan® probe assay FLJ12443 ID
Hs00227357_m1 (Applied Biosystems) as recommended by the manufacturers and run on a
7500 Fast Real-Time PCR system (Applied Biosystems). Results were normalized against
UBC as previously described [11].
Plasmid construction
Wild-type hLPCAT1 cDNA was PCR amplified from the marathon ready colon colorectal
adenocarcinoma cDNA library (Clontech) and cloned into pcDNA bidirectional (Invitrogen)
using primers sense 5′-GGCGGCCATGGCTGCGGGGATG and antisense 3′-
CTAATCCAGCTTCT TGC GACAGGC. Subsequently, hLPCAT1, lacking the TGA stop
codon, was cloned into pcDNA3.1/V5-His (Invitrogen). hLPCAT1 was cloned into
pGEX-1λT (GE Healthcare) using primers sense BamHI-
CGGATCGGATCCATGAGGCTGCGGGGATGC and antisense EcoRI
ACGAGAGAATTCATCCAGCTTCTTGCGAACAGGC and standard cloning techniques.
All DNA sequences were verified.
SNP analysis
Chromosomal DNA from 288 normal samples and 104 tumor samples were prepared using
Puregene, Genomic DNA purification kit (Gentra Systems, Minneapolis, MN, USA). Single
nucleotide polymorphism (SNP) analysis was performed using a custom TaqMan® SNP
genotyping assay (BAB SNP-1397, Applied Biosystems) following the manufacturer’s
instructions. Messenger RNA (mRNA) isolated from eight tumor samples was converted to
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cDNA using Superscript™ cDNA synthesis kit (Invitrogen), and the single PCR fragment
expanding the SNP region was amplified and sequenced.
Production of monospecific antibodies
Polyclonal rabbit anti-LPCAT1 antibodies #EP389/SD25 were raised against the peptide
CADFSPENSDAGRKPV (amino acids 514–529), conjugated to KLH. Antisera were
affinity purified against the peptide (Eurogentec, Belgium).
Immunohistochemistry
Immunohistochemical analyses were performed on 4-µm paraffin-embedded formalin fixed
(FFPE) specimens from colon adenocarcinomas and normal colon mucosa from the
resection edges as previously described [12]. A multiple cancer tissue microarray (TMA)
“T8235713-5-BC” (BioCat, Germany) was stained for LPCAT1 expression using unpurified
rabbit anti-LPCAT1 (1:250).
Immunofluorescence microscopy
COS7 cells were cultured in RPMI 1640 medium supplemented with 10% fetal calf serum
and 1% penicillin-streptomycin at 37°C and 5% CO2 and transfected using Lipofectamine
(Invitrogen) following the manufacturer’s instructions. Transfected COS7 cells were fixed
and permeabilized with cold methanol (−20°C) at room temperature. Cells were stained with
affinity chromatography purified rabbit anti-LPCAT1 (1:50), mouse monoclonal anti-
prohibitin (1:50; Abcam), and mouse monoclonal anti-calreticulin, (1:40; Biovision).
Secondary antibodies were goat anti-rabbit highly cross-adsorbed Alexa®Fluor 488
conjugated (Molecular Probes (1:2000)) in combination with goat anti-mouse Alexa®Fluor
546 conjugated (Molecular Probes (1:800)). Cells were stained with 4′,6-diamidino-2-
phenylindole for nuclear visualization. Cells were mounted with Fluorescent Mounting
Medium, DakoCytomation. Visualization was performed using a Zeiss Axiovert200M plus
apotom fluorescence microscope with × 1,000 magnification. Images were merged using
axiovision software.
Cell extraction, SDS gels, and Western blots
COS7 and SW480 cells transfected as above were harvested and lysed in lysis buffer (50
mM Tris–HCl pH 8.0, 150 mM NaCl, 1 mM dithiothreitol (DTT), 1% Triton X-100, and
protease inhibitor Roche complete, ethylenediaminetetraacetic acid (EDTA) free). Twenty to
30 µg total protein samples were run in 12% sodium dodecyl sulfate (SDS) gels (Invitrogen)
and transferred to nitrocellulose membranes. Membranes were blocked with 3% w/v non-fat
powdered milk phosphate-buffered saline (PBS). The primary antibody was rabbit
polyclonal unpurified anti-LPCAT1 (1:100) or rabbit anti-V5 (3 µg; Abcam) and the
secondary antibody swine anti-rabbit HRP conjugated (1:5,000). The immunoreactive bands
were visualized using ECL plus (Amersham Biosciences) and a UVP ChemiDoc-It, Imaging
system, (UVP).
Proliferation assay
Cell proliferation assays were performed on COS7 cells and human SW480 colon cancer
cells using CyQUANT® NF, Invitrogen. Briefly, 400 cells (COS7 or SW480) were plated
per well. Cells were transfected as described above. After transfection, 1× dye binding
solution was added at different times post-transfection, and fluorescence intensities were
measured using a Biotek FLEX800-TBIDE fluorescence microplate reader at excitation
485/20 nm and detection 528/20 nm. Analyses were performed on 24 independent wells per
time point and per plasmid construction.
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LPCAT and AGPAT activity assays
COS7 cells in 100 mm dishes (5×106) were transfected with 10 µg pcDNA3.1/vector control
or LPCAT1 construct using an Amaxa nucleofector, program A-24 in solution V. Twenty-
four hours after transfection, cells were washed twice in PBS, resuspended in medium I (250
mM sucrose, 10 mM Tris–HCl pH 7.4, 1 mM EDTA), and homogenized with ten up and
down strokes in a motor-driven Teflon-glass homogenizing vessel. Large debris and nuclei
were removed by centrifugation at 600×g. Protein concentrations were determined by the
bicinchonic acid method (Pierce).
The LPCAT assay was performed essentially as described previously [4]. The reaction
contained 80 mM Tris, pH 7.6, 5 mM MgCl2, 30–50 µM [14C]palmitoyl- or [14C] linoleoyl-
CoA, and 50–200 µM 1-palmitoyl-lysophosphatidylcholine in a final volume of 100 µl. The
assay was started by the addition of 5–10 µg post-nuclear supernatant from empty vector or
LPCAT1 transfected COS7 cells, incubated at 30°C for 5 min and stopped by spotting 15 µl
of the reaction mixture onto an LK6 thin layer chromatography (TLC) plate (Whatman) with
authentic lipid standards (Avanti Polar Lipids). The plates were developed in CHCl3/MeOH/
H2O (65:25:4) and [14C] incorporated into phosphatidylcholine was determined by Bioscan
analysis. Standards were visualized by exposure to iodine vapor.
AGPAT specific activity was assayed at 37°C in a 100-µl mixture containing 100 mM
HEPES-NaOH pH 7.5, 200 mM NaCl, 10 mM EDTA, 8 mM NaF, 1 mg/ml bovine serum
albumin (fatty acid free), 1 mM DTT, 5% (w/v) glycerol, 40 µM oleoyl-CoA, and 20 µM 1-
[3H]oleoyl-LPA (1 µCi, Perkin-Elmer NET-1100). The reaction was initiated by adding 8
µg post-nuclear supernatant to the assay mixture. Fifteen microliters of the reaction mixture
was removed at 2, 4, and 6 min and spotted directly onto a Silica H plate (Analtech) together
with authentic standards (Avanti). The radiolabeled phosphatidic acid (PA) product was
separated from the radiolabeled lysophosphatidic acid (LPA) substrate in chloroform/
pyridine/formic acid (88.5%) (50:30:7; v/v). Authentic lipid standards for LPA and PA were
visualized by exposure to iodine vapor. Spots corresponding to PA were scraped into 500 µl
methanol/water (1:1), Ecolite (ICN) was added, and radioactivity was quantified by
scintillation counting.
Lipid metabolism
COS7 or SW480 cells in 60-mm dishes (1×106 cells) were transfected with 4 µg hLPCAT1:
pcDNA3.1/V5-His or a pcDNA3.1/topo vector control. Twenty-four hours later, cells were
incubated with trace (3 µM) or 100 µM [14C] oleate (54.6 mCi/mmol) or [14C]palmitate
(57.5 mCi/mmol) (Perkin Elmer). After 3 h, cells were scraped and lipids were extracted
into chloroform [13] and separated by TLC on silica gel G plates with CHCl3/methanol/
acetic acid/H2O (50:37.5:3.5:2, v/v) together with authentic standards (Avanti, Alabaster,
AL). Areas conforming to PC, PE, PI, and neutral lipids were counted on a Bioscan System
200 imaging scanner.
Choline metabolites
COS7 cells in 100-mm dishes were transfected with LPCAT1 or a pcDNA3.1/vector control
(8 µg) with Lipofectamine (24 µg). Thirty hours later, the cells were scraped from each dish
into 0.5-ml ice cold PBS, and 2 ml of ice cold methanol was added before choline and its
metabolites were measured. Protein was measured by the bicinchoninic acid method (Pierce)
using bovine serum albumin as the standard. Aqueous and organic compounds were
separated, analyzed, and quantified directly using liquid chromatography/electrospray
ionization-isotope dilution mass spectrometry after the addition of internal standards labeled
with stable isotopes to correct for recovery [14].
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We have expanded the previous work on pooled CRC samples [2] using genome-wide
expression profiling of a human genome U133plus2.0 microarray. We found overexpression
of the transcript corresponding to probe 201818_at (AYTL2) in colon adenocarcinomas when
compared to normal mucosa (Fig. 2a,b). Our study showed a significant overall 2.5-log2-
fold change (p<10−8), and a 0.8 log2-fold increase between the MSS and MSI subgroups
(p<10−7) (Table 2). RT-PCR analysis of 20 independent samples using a TaqMan probe
against AYTL2 confirmed the upregulation in adenocarcinomas compared to their matching
normal mucosa from the resection edge (Fig. 2c). The overexpression of LPCAT1 transcript
in CRC compared to normal mucosa is consistent in both analyses. A very low transcript
level of human LPCAT1 in normal colon has recently been reported, supporting our results
[5].
LPCAT1 protein is highly expressed in colon adenocarcinoma
Immunohistochemical analysis using anti-hLPCAT1 antibody was performed on FFPE from
previously expression-profiled adenocarcinomas and specimens from their matching normal
mucosa [15,16]. The matching normal mucosa showed weak LPCAT1 expression in the
cytoplasm of the luminal part of the mucosa. The LPCAT1 protein was strongly upregulated
in adenocarcinomas, showing an overall staining varying from moderate to very strong, even
at early stages (Fig. 3). Total cell extracts from transiently transfected COS7 cells subjected
to Western blot confirmed the specificity of the LPCAT1 antibody (Fig. 4i–j).
Upregulation was independent of Dukes stage, colon or rectum precedence, and only
minimal (log2 ratio 0.2) although significant (p=0.04) between stages 2 and 3 (Table 1).
LPCAT1 is upregulated in several human cancers
Using a multiple cancer TMA, we analyzed the LPCAT1 protein expression pattern in 94
samples taken from 46 cancers from different locations and from 46 normal tissues.
LPCAT1 was moderately or strongly expressed in normal human tissues (Fig. 1 and Table 1
in the Electronic supplementary material). Only normal ovary, pancreas, parotid, rectum,
skin, and tongue were negative. All the tumor tissues, with the exception of those from
adrenal gland, showed the same or stronger intensity than that of the normal tissues.
LPCAT1 was strongly expressed in samples from normal and cancerous lung and liver.
Compared to normal colon and rectum mucosa, tumor samples showed overexpression of
LPCAT1, consistent with the results obtained by immunohistochemical analysis of single
samples and their matching mucosa. In summary, microarray data, RT-PCR, and
immunohistochemistry all showed transcript and protein upregulation of LPCAT1 in
colorectal cancer compared to normal mucosa.
SNP analysis
Amplification of the LPCAT1 cDNA coding sequence from an adenocarcinoma colorectal
cDNA library identified a SNP, rs35452723, in position 1397, which causes a single amino
acid mutation (M427T) in the corresponding codon sequence ATG/ACG. Because no
validation status or heterozygosity was available, we performed a custom genotyping assay
on more than 300 samples to determine whether a correlation exists between the identified
mutation and the cancer phenotype. As shown in Table 2 in the Electronic supplementary
material, we found no differences between the relative genotypic frequency of the ATG/
ATG, ATG/ACG, or ACG/ACG alleles between normal individuals and colorectal cancer
patients. In fact, 8% of the population tested was homozygotic for the M427T mutation
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irrespective of cancer status. The M427T mutation lies beyond the glycerophosphate
acyltransferase motifs [17], so this SNP probably does not significantly affect the activity or
function of the protein.
Subcellular localization
Bioinformatic programs SOSUI (http://bp.nuap.nagoya-u.ac.jp/sosui/sosui_submit.html) and
TMHMM (http://www.cbs.dtu.dk/services/TMHMM-2.0/) predicted the presence of a single
transmembrane inside–outside segment of approximately 21 aa at the N terminus. This
putative transmembrane helix suggested that the protein may bind to a membrane at its N-
terminal end leaving the active site facing the cytoplasm as described for mitochondrial
outer-membrane proteins such as Tom20, Tom70, and GPAT1 [18,19]. Moreover, topology
prediction assessed by TargetP 1.1 (http://www.cbs.dtu.dk/services/TargetP/) suggested a
potential mitochondrial localization. Although previous reports [3–5] had suggested an ER
localization, we found that hLPCAT1 co-localizes with marker proteins on both the ER and
the mitochondria. Immunofluorescence analysis in transiently transfected COS7 cells
showed co-localization of LPCAT1 with the mitochondrial marker prohibitin in a diffused
punctate pattern (Fig. 4H) and with the ER-marker calreticulin (Fig. 4d). Interestingly, in a
time-based experiment, the overexpressed protein was present in the Golgi apparatus at
about 12 h after transfection and was subsequently found in its final location in the
mitochondria and ER (data not shown).
Proliferation assay
Green monkey kidney COS7 cells and the colon cancer cell line SW480 cells were
transfected with LPCAT1. COS7 cells showed no difference in proliferation rate from 0 to
72 h. Thirty hours after transfection with LPCAT1, SW480 colon cancer cells showed an
increased (p<10−5) rate of proliferation compared to cells transfected with an empty vector
(Fig. 5).
LPCAT1 activity and lipid metabolism
Previous studies have shown that the mouse LPCAT1 homolog exhibits acyltransferase
activity with several acyl-CoA donors and LysoPtdCho acceptors [3–5]. Our human
LPCAT1 clone also exhibits robust LPCAT activity. COS7 cells transfected with LPCAT1
had a 38-fold higher specific activity with [14C]palmitoyl-CoA as acyl-donor than empty
vector transfected cells (Fig. 6a). A sevenfold increase in LPCAT activity was observed
when [14C]linoleoyl-CoA was used as acyl-donor. In contrast to a report suggesting that
LPCAT1 has 1-acylglycerol-3-phosphate acyltransferase (AGPAT) activity [5], AGPAT
activity was identical in LPCAT1 transfected COS7 cells (4.56 nmol min−1 mg protein−1)
and in control cells (4.46 nmol min−1 mg protein−1).
Compared with cells transfected with an empty vector, COS7 cells transfected with
LPCAT1 showed no change in the incorporation of either trace or 100 µM [14C]oleate into
PtdCho (Fig. 7A (a,b)). However, with trace (~3 µM) or 100 µM [14C]palmitate added to the
medium, incorporation into PtdCho was enhanced 25% and 63%, respectively, in the
LPCAT1 transfected cells (Fig. 7A (c,d)). Interestingly, overexpression of LPCAT1 in the
presence of 100 µM palmitate reduced the amount of label incorporation into neutral lipid
(predominantly triacylglycerol) (Fig. 7A (d)). No changes were observed in other lipids
under any condition (dpm were 20,000–45,000; n=3 for each condition). When SW480 cells
were transfected with an empty vector or with LPCAT1, we observed similar results (Fig.
7B). In these cells, the presence of LPCAT1 resulted in less [14C]oleate incorporation into
PtdCho (Fig. 7B (a,b)), whereas trace or 100 µM [14C]palmitate incorporation into PtdCho
(Fig. 7B (c,d)) was enhanced 19% or 31%, respectively. Despite the marked differences in
radiolabeling with palmitate, we observed no differences in the amounts of PtdCho or
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choline metabolites in LPCAT1 transfected COS7 cells as compared with the empty vector
transfected cells (Table 3).
Discussion
The major findings of our study were that NM_024830.3 (previously called FLJ12433) was
upregulated in human CRC compared to normal mucosa and encodes a protein with
lysophosphatidylcholine acyltransferase activity rather than AGPAT activity. Overexpressed
hLPCAT1 catalyzed the reacylation of LysoPtdCho, co-localized both to ER and
mitochondria and significantly increased the growth rate of the colon cancer cell line
SW480.
These findings suggest the importance of PtdCho metabolism in CRC. Increased abundance
of the LPCAT1 protein was verified in CRC mucosa, which showed increased LPCAT1
staining compared to matching normal mucosa from the same patients. This upregulation in
CRC was independent of the antibody used (polyclonal rabbit anti-hLPCAT1 serum or
affinity chromatography purified). We extended the study to a tissue microarray with 46
tumors from different organ sites and their corresponding normal tissues. LPCAT1 was
widely expressed in the human tissues. However, with the exception of adrenal tumors,
protein expression was always at the same or a higher level in the cancer samples. The high
protein expression in normal lung is consistent with previous RT-PCR analyses in mouse
and with Northern blot analyses in rat and human tissues [3–5]. Expression was also very
high in normal liver, perhaps related to the large amount of PtdCho synthesis required to
replete losses in bile and secreted very-low density lipoprotein.
Although mouse and rat LPCAT1 were both characterized as lysophosphatidylcholine
acyltransferases that prefer to use palmitate rather than oleate [3,4], the human LPCAT1 was
reported to be an acylglycerol-3-phosphate acyltransferase isoform (called AGAPT9) that
lacks LPCAT activity [5]. To determine the enzymatic activity of the human LPCAT1, we
overexpressed hLPCAT1 in COS7 cells. LPCAT1 specific activity increased 38-fold with
palmitate as the acyl-donor, but AGPAT activity did not increase, indicating that the
transfected plasmid encodes an enzyme that catalyzes only LPCAT activity. Lack of LPCAT
activity in the previous publication [5] may have resulted from a problem related to the
location of the epitope tag, since our hLPCAT1 contains a V5-His epitope tag at the C-
terminal rather than at the N-terminal.
Confirming the LPCAT activity, COS7 or SW480 cells incubated with [14C]oleate or
[14C]palmitate showed enhanced incorporation of palmitate, but not oleate, into PtdCho; the
COS7 cells also showed a concomitant decrease in [14C]palmitate incorporation into
triacylglycerol. Despite the higher reacylation of cellular LysoPtdCho in COS7 cells, the
cells did not accumulate PtdCho or choline metabolites. This finding suggests that enhanced
reacylation of LysoPtdCho may alter the turnover rate of PtdCho in cell membranes rather
than their PtdCho. Furthermore, COS7 cells transfected with hLPCAT1 did not grow more
rapidly or differ morphologically from COS7 cells transfected with the vector alone. A
similar result was reported when rat liver CTP/phosphocholine cytidylyltransferaseα (CCTα)
or human CCTβ were overexpressed in COS7 cells [20,21]. Despite an increased rate of
PtdCho synthesis in these cells, PtdCho did not accumulate. Instead, the rate of PtdCho
degradation was accelerated, and excess glycerophosphocholine (GPC) was released into the
media [22]. These results suggest that general membrane phospholipid homeostasis is
achieved by coordinated phospholipid synthesis and degradation to GPC via phospholipase
A2 activities. This homeostatic balance changes drastically in cancer. Both cellular
phosphocholine and total choline metabolites are elevated in cancer cells and solid tumors
[23]. Whereas normal cells contain high amounts of GPC and low amounts of
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phosphocholine and total choline metabolites, in breast and ovarian cancers that progress to
a malignant phenotype, one finds a low content of GPC and high amounts of
phosphocholine and total choline metabolites [24]. This alteration is also observed in other
types of cancer in which the amounts of phosphocholine and PtdCho accumulate [25].
CRC cells exhibit changes in both phospholipid composition and charge [9]. Moreover,
PtdCho is the most prominent phospholipid species in both tumor and normal mucosa from
colorectal tissues, and PtdCho content (µg lipid/g wet tissue) is increased in CRC [8]. The
unaltered phospholipase A activity together with decreases in the activities of
phospholipases C and D has suggested that attenuated PtdCho hydrolysis may explain the
accumulation of PtdCho [8]. It has also been suggested that the increased synthesis of
PtdCho could result from enhanced CTP/phosphocholine cytidylyltransferase activity
caused by the presence of increased levels of the cytidylyltransferase protein [8], the rate-
limiting step in the synthesis of PtdCho [26] (Fig. 1). Our studies suggest that LPCAT
activity provides yet another mechanism for maintaining a high cellular content of PtdCho.
The importance of phospholipid metabolism in tumor growth is also suggested by the
finding that phosphocholine (also known as phosphorylcholine) is present at high
concentrations in human colon cancer specimens due, in part, to an increase in choline
kinase activity [27]. Choline kinase protein is overexpressed in tumor-derived cell lines and
in lung, prostate, and colorectal human cancers [28], and it may play a role in malignant
transformation. In breast cancer, the net increase in phosphocholine can be explained by
choline kinase, pancreas-enriched phospholipase C and phospholipase C β3 mRNA
upregulation, together with lysophospholipase 1, phospholipase A2 Group IVA, and
phospholipase D1 downregulation [29] (Fig. 1). Our CRC microarray analysis not only
supports this general mechanism, but also shows some differences indicating diversity
among different types of cancer (Fig. 1, Table 4).
We hypothesize that in CRC, the accumulation of PtdCho, independent of its source, is
probably favored by the downregulated transcription of phospholipases A2 together with
reduced phospholipase D1, D2, and C transcription and activity (Table 4). In addition,
overexpression of LPCAT1 can recycle lysophosphatidylcholine to PtdCho preferentially in
the dipalmitoyl form [3]. This hypothesis is strengthened by the enhanced growth rate
observed for SW480 colon cancer cells that overexpressed LPCAT1, but not in LPCAT1-
transfected COS7 cells, which maintain a homeostatic phospholipid balance.
What is the effect of a high cellular PtdCho and phosphocholine content in colon cancer?
Phospholipid accumulation increases the surface density of positively or negatively charged
groups depending on the local pH values. An increase in the superficial membrane potential
is associated with progress of malignancies [9], and an increase in membrane fluidity
influences metastases because it affects cell adhesion [30]. In this context, shorter or
unsaturated fatty acids of phospholipids reduce the Tm and change membrane curvature,
thickness, and fluidity. Such changes in lipid profiles are specific to the cancer type [10] and
may influence potential therapies because the dynamic and structural properties of lipid
membranes can affect drug delivery by peptide-loaded liposomes [31].
In conclusion, we have described the upregulation of LPCAT1 in colorectal cancer
adenocarcinomas compared to normal mucosa. The location of LPCAT1 in the ER and
mitochondria links it to a functional role in recycling LysoPtdCho and increasing the
palmitate content of PtdCho. Both PtdCho and phosphocholine are upregulated in CRC and
exert an important although not fully understood role, in oncogenicity, including increased
cell proliferation. We hypothesize that LPCAT1 contributes to total choline metabolite
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accumulation in CRC via enhanced PtdCho recycling and to alter the specific lipid profile
found in CRC.
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Role of hLPCAT1 in phosphatidylcholine metabolism. hLPCAT1 catalyzes the conversion
of LysoPtdCho into PtdCho using palmitate preferentially as its substrate. The enzymes
involved in PtdCho metabolism are highlighted in gray squares. PLC* phospholipase C, the
activity that hydrolyzes phsophatidylcholine to DAG and P-choline has not yet been
characterized in human; CK choline kinase; CCT CTP/phosphocholine cytidylyltransferase;
PLD phospholipase D; DGCPT diacylglycerol cholinephosphotransferase; PLA2
phospholipase A2; GPCPD glycerophosphocholine phosphodiesterase; PLB/LPL
phospholipase B or lysophospholipase; SM synthase sphingomyelin synthase. Metabolites
are DAG diacylglycerol, PtdCho phosphatidylcholine, LysoPtdCho lysophosphatidylcholine,
GPC glycerophosphocholine
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Microarray analysis of 168 samples representing molecular subgroups of colorectal cancers
and real-time PCR analysis. a Transcript expression level of LPCAT1 on the U133plus2.0
Gene Chip. The black bars correspond to colorectal cancer samples, the gray bars to normal
mucosa. Expression values are given as log2 values and all data are normalized. b MSS/MSI
study. Median log2 values and standard deviations of normal biopsies (median normal,
n=10), colorectal cancer patients (median cancer, n=168), microsatellite instable MSI (CRC
patients with MSI, n=35), microsatellite stable MSS (CRC patients with MSS, n=118). c
Real-time PCR analysis was performed in triplicates using TaqMan® probe assay FLJ12443
ID Hs00227357_m1. Each column represents a single sample. Five MSI (gray) and MSS
(black) tumor samples named T1–T5, T6–T10 are represented together with their normal
matching mucosa (white) named N1–N10. The relative intensity of LPCAT transcript has
been normalized against ubiquitin
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Immunohistochemical analysis of the expression of hLPCAT1 in four colon
adenocarcinomas (T) and their respective matching normal mucosas (N). Magnification ×20
using unpurified rabbit anti-LPCAT1 (1:250). a, c, e, h Normal mucosa; b, d, f, i colon
adenocarcinoma; k normal mucosa; and l colon adenocarcinoma from a commercial tissue
microarray, ×20 magnification; g, j, m zoomed images from f, i, and l, ×40 magnification
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Localization of hLPCAT1 at two different sites in transiently transfected COS7 cells. a–d
Co-localization of LPCAT1 with the ER marker calreticulin. a LPCAT1, b nucleus c
calreticulin, d merged image (a–c). e–h Co-localization of LPCAT1 with the mitochondrial
marker prohibitin, e LPCAT1, f nucleus, g prohibitin, h merged image. Western blot (i–j)
COS7 cells transiently transfected with recombinant i hLPCAT1-V5-His or j hLPCAT1.
Whole-cell extract detection with anti-V5 antibody (i) or unpurified rabbit anti-hLPCAT1
(j). i MW Molecular weight marker, 1 LPCAT1-V5-His, 2 mock, empty vector. j MW
Molecular weight marker, 1 mock, empty vector, 2 LPCAT1
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Proliferation assay Green monkey kidney COS7 cells and colorectal carcinoma SW480 cells
were transiently transfected with hLPCAT1 or a mock, empty vector. Cell proliferation rate
was compared at different time points. The median value of 24 independent wells is shown
together with the standard deviation. After 30 h LPCAT1 transfected SW480 cells showed a
significantly (asterisk) increased proliferation rate compared to cells transfected with an
empty vector (mock). No increased proliferation rate was detected in COS7 cells transfected
with hLPCAT1. *p values are p<10−5, p<10−11, and p<10−6 after 30, 48, and 72,
respectively
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a–c Functional characterization of hLPCAT1. LPCAT1 activity was assayed as described in
“Materials and methods.” Post nuclear supernatant was isolated from COS7 cells transfected
with empty vector (V) or LPCAT1-V5 (AT) and assayed in the presence of [14C] palmitoyl-
CoA or [14C]linoleoyl-CoA. Data are representative of an experiment repeated three times.
Fatty acid incorporation into COS7 cells transfected with LPCAT1 (AT) or a vector control
(V). Twenty-four hours after transfection, cells were incubated with trace or 100 µM
[14C]oleate or [14C]palmitate. After 60 min, cells were scraped and lipids were extracted
into chloroform and separated by thin layer chromatography together with authentic
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standards. [14C] Fatty acid incorporation into lipids was determined by Bioscan analysis.
Incorporation of [14C]oleate or [14C]palmitate into b neutral lipids or c PtdCho
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hLPCAT increases phosphatidylcholine synthesis from palmitate. Fatty acid incorporation
into a COS7 cells or b SW480 cells transfected with LPCAT1 or a vector control. Twenty-
four hours after transfection, cells were incubated with trace or 100 µM [14C] oleate or
[14C]palmitate. After 3 h, cells were scraped and lipids were extracted into chloroform and
separated by thin layer chromatography together with authentic standards. [14C] Fatty acid
incorporation into lipids was determined by Bioscan analysis. Incorporation of [14C]oleate
(a, b) or [14C]palmitate (c, d) into neutral lipids (NL), phosphatidylethanolamine (PE),
phosphatidylinositol (PS), or phosphatidylcholine (PC). *p<0.05, **p<0.001. c Western blot
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showing SW480 cells transfected with recombinant hLPCAT1-V5-His (vector) or
hLPCAT1 and detected with anti-V5 antibody
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Table 1
Microarray analysis résumé table and clinical specimens
Tumor specimens (168) Normal specimens (10) p value
Gender
  Male 91 8
  Female 77 2
Age
  <50 years 12
  50–70 years 89 6




  A 1 0.69
  B 149
  C 13
  D 5
Grade
  1 20 0.04
  2 115
  3 30
  N.D. 3
MSS/MSI
  MSS 118
  MSI 35
  ND 15
Clinical specimens gender, age, Duke’s stages, grade and MSS/MSI status. p value colon/rectum, Duke’s B/A, C. D and grade 2/3
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Table 2
Summary of microarray transcript profiling
N T Fold change p value
LPCAT1 5.5 8.0 2.5 <10−8
MSI 8.6 3.1 MSI/MSS
MSS 7.8 2.3 <10−7
Data are given as median log2, fold change between normal (N) and tumor (T) and p-value.
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Table 4
Microarray analysis of enzymes involved in phosphatidylcholine metabolism
Protein Normal MSS MSI
Choline kinase 6.4 6.5 6.3
Choline kinase 7.0 7.1 6.8
Lysophospholipase 1/phospholipase B 8.6 9.3+ 8.8
Lysophospholipase 1/phospholipase B 10.8 11.1+ 11.1+
Phospholipase A2 Group IVA 6.6 4.3− 6.3−
Pancreas-enriched phospholipase C 9.3 6.3− 6.7−
Pancreas-enriched phospholipase C 9.0 5.9− 6.5−
Phospholipase C β3 6.5 9.1+ 9.3+
Phospholipase D1 7.0 5.2− 5.3−
Phospholipase D1 5.3 3.5− 3.6−
Phospholipase D2 6.0 5.7− 6.0
CTP phosphocholine cytidylyltransferase ud ud ud
Diacylglycerol phosphotransferase 10.7 10.2− 9.9−
Phospholipase A2 group X 10.0 6.7− 7.0−
Phospholipase A2 groupXIIA 7.7 7.3− 7.6
Phospholipase A2 group XIIA 6.4 6.5 6.8+
Phospholipase A2 group XIIB ud ud ud
Phospholipase A2 group IB ud ud ud
Phospholipase A2 group IIA 10.1 9.0+ 10.9+
Phospholipase A2 group IID ud ud ud
Phospholipase A2 group IIE ud ud ud
Phospholipase A2 group IIF ud ud ud
Phospholipase A2 group III ud ud ud
Phospholipase A2 group V ud ud ud
Phospholipase A2 group VI ud ud ud
Enzymes from choline kinase to phospholipase D2 correspond to those reported to be differentially expressed in breast cancer [29]. Data are given
as median log2-fold change between normal (N) and tumor (MSS microsatellite stable or MSI microsatellite unstable) and with p<0.05. ud under
detection, reflects log2 values<5.0 considered as background
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